Skip NavigationSkip to Content

Phosphonic acid-containing inhibitors of tyrosyl-DNA phosphodiesterase 1

  1. Author:
    Zhao,Xue Zhi
    Wang, Wenjie
    Lountos,George
    Tropea, Joseph E
    Needle,Danielle
    Pommier, Yves
    Burke,Terrence
  2. Author Address

    Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, United States., Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Center for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States.,
    1. Year: 2022
    2. Date: Aug 16
    3. Epub Date: 2022 08 16
  1. Journal: Frontiers in Chemistry
    1. 10
    2. Pages: 910953
  2. Type of Article: Article
  3. Article Number: 910953
  1. Abstract:

    Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs stalled type I topoisomerase (TOP1)-DNA complexes by hydrolyzing the phosphodiester bond between the TOP1 Y723 residue and the 3'-phosphate of its DNA substrate. Although TDP1 antagonists could potentially reduce the dose of TOP1 inhibitors needed to achieve effective anticancer effects, the development of validated TDP1 inhibitors has proven to be challenging. This may, in part, be due to the open and extended nature of the TOP1 substrate binding region. We have previously reported imidazopyrazines and imidazopyridines that can inhibit TDP1 catalytic function in vitro. We solved the TDP1 crystal structures with bound inhibitors of this class and found that the dicarboxylic acid functionality within the N-(3,4-dicarboxyphenyl)-2-diphenylimidazo [1,2-a]pyridin-3-amine platform overlaps with aspects of phosphoryl substrate recognition. Yet phosphonic acids could potentially better-replicate cognate TOP1-DNA substrate binding interactions than carboxylic acids. As reported herein, we designed phosphonic acid-containing variants of our previously reported carboxylic acid-containing imidazopyrazine and imidazopyridine inhibitors and effected their synthesis using one-pot Groebke-Blackburn-Bienayme multicomponent reactions. We obtained crystal structures of TDP1 complexed with a subset of inhibitors. We discuss binding interactions of these inhibitors within the context of phosphate-containing substrate and carboxylic acid-based inhibitors. These compounds represent a new structural class of small molecule ligands that mimic aspects of the 3'-processed substrate that results from TDP1 catalysis. Copyright © 2022 Zhao, Wang, Lountos, Tropea, Needle, Pommier and Burke.

    See More

External Sources

  1. DOI: 10.3389/fchem.2022.910953
  2. PMID: 36051621
  3. PMCID: PMC9424690
  4. PII : 910953

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel